iShares Global Healthcare

Lilly China Launches "Tuo Hu Chang An" Patient Assistance Program to Support IBD Patients

UCB's Bimzelx Beats AbbVie's Skyrizi in Head-to-Head Psoriatic Arthritis Study with Superior Joint Outcomes

Johnson & Johnson Expected to Grow Sales 7% in 2026, Seen as Strong Investment Due to Stable Model and Dividend History

Zacks Raises UnitedHealth's Q1 2027 EPS Estimate to $6.87

Eli Lilly & UNICEF Launch US$50m Partnership Program for Childhood Chronic Diseases

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Multiple Institutional Investors Disclose Increased Stakes in UnitedHealth Group on May 19, 2026

Lilly Asia Ventures Participates in Accro Bioscience's $50 Million Series C Financing

Institutional Investor Larson Financial Group LLC Reduces Stake in Eli Lilly

Investment firm Gambit Capital Management makes a new $26.54 million investment in Eli Lilly

Wells Fargo Raises UnitedHealth Group's Price Target to $397

Japan Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea

Eli Lilly Scales Up AI-Driven Drug R&D and Production with Dell Solutions

Merck Plans to Issue $6 Billion in Bonds to Fund Terns Pharmaceutical Acquisition

Judge grants Luigi Mangione's request to suppress evidence in UnitedHealth CEO murder case

UnitedHealth Group will hold its Annual General Meeting on June 2, 2026

Harbour BioMed releases positive preclinical obesity data on its potential rival drug, LET003

Merck Announces Experimental Endometrial Cancer Drug Meets Primary Endpoint in Late-Stage Trial

Novo Nordisk plans to launch Wegovy oral weight-loss drug outside the US, intensifying competition with Eli Lilly

Eli Lilly announces its RET kinase inhibitor selpercatinib has entered a Phase III clinical trial for the first-line treatment of RET fusion-positive lung cancer

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

InMed Pharmaceuticals

Amesite

Meiwu Tech

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

CN Energy

NextNRG

MetaVia

Generation Income Properties

Co-Diagnostics

Pinned News

置顶新闻

ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD

The latest batch of 13F filings has been released: In Q1, Berkshire Hathaway increased its stake in Google Class A shares by over 200%, propelling it to the position of its seventh-largest holding. The firm completely exited positions held for nearly seven years—including Amazon, as well as Visa, Mastercard, and UnitedHealth—while simultaneously making a return to the airline sector after a six-year hiatus, investing $2.65 billion to establish a new position in Delta Air Lines. Bridgewater Associates, meanwhile, initiated new positions in TSMC and the Gold ETF (GLD) for the first time; it also increased its holdings in Amazon (elevating it to its top holding), Nvidia, Broadcom, and Micron. Conversely, the firm liquidated its stakes in Salesforce and ServiceNow, and trimmed its positions in Mastercard, Adobe, and others. Institutional capital is currently converging on AI computing power and safe-haven assets. How many of the stocks in your portfolio have caught the eye of these investment giants?

The latest batch of 13F filings has been released: In Q1, Berkshire Hathaway increased its stake in Google Class A shares by over 200%, propelling it to the position of its seventh-largest holding. The firm completely exited positions held for nearly seven years—including Amazon, as well as Visa, Mastercard, and UnitedHealth—while simultaneously making a return to the airline sector after a six-year hiatus, investing $2.65 billion to establish a new position in Delta Air Lines. Bridgewater Associates, meanwhile, initiated new positions in TSMC and the Gold ETF (GLD) for the first time; it also increased its holdings in Amazon (elevating it to its top holding), Nvidia, Broadcom, and Micron. Conversely, the firm liquidated its stakes in Salesforce and ServiceNow, and trimmed its positions in Mastercard, Adobe, and others. Institutional capital is currently converging on AI computing power and safe-haven assets. How many of the stocks in your portfolio have caught the eye of these investment giants?

Big funds' 13Fs are out: betting on AI compute and safe havens

GILD

ARKG

LABU

SBIO

IBBQ

ProShare Advisors LLC increased its stake in Gilead Sciences, Inc. by 39.1% in Q4, acquiring 623,752 shares, bringing its total to 2,217,290 shares valued at $272.15 million. Other institutional investors also adjusted their holdings. Gilead's stock opened at $129.67, with a market cap of $160.99 billion. The company reported $2.03 EPS, exceeding estimates, and announced a quarterly dividend of $0.82 per share.

Market Beat

Gilead Sciences

Gilead Sciences, Inc.

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

VG Health

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

VanEck Biotech ETF

iShares US Pharma

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

BeOne Medicines (NASDAQ:ONC) has achieved an annualized return of 26.69% over the past decade, outperforming the market by 13.23%. A $100 investment in ONC 10 years ago would now be worth $1,057.17, reflecting the significant impact of compounded returns. The company's current market capitalization stands at $29.88 billion.

benzinga_article

Beigene

Here's How Much $100 Invested In BeOne Medicines 10 Years Ago Would Be Worth Today

Sanofi reported 1.21 billion issued shares and 1.33 billion real voting rights as of April 30, 2026. Theoretical voting rights, including treasury shares, stood at 1.35 billion.

PUBT

Sanofi

Sanofi reports 1.21 billion issued shares, 1.33 billion real voting rights as of April 30

Sanofi has provided information regarding its total number of voting rights and shares as of April 30, 2026. The company has issued 1,212,212,936 shares, with 1,329,027,146 real voting rights (excluding treasury shares) and a theoretical total of 1,346,241,660 voting rights (including treasury shares). This information complies with French commercial regulations.

GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - April 2026

WELL

10:46 AM EST - WELL Health Technologies Corp. : Announced that the Notice of Intention to Make a Normal Course Issuer Bid it filed with the Toronto Stock Exchange has been approved by the TSX and has subsequently entered into an automatic share purchase plan with a broker in order to facilitate repurchases of the Company's common shares. The NCIB is a renewal of its NCIB that is set to expire on May 19. WELL Health Technologies Corp. shares T.WELL are trading down $0.015 at $3.94.

Baystreet

Welltower Op

SPDR S&P Health

iShares US Healthcare Providers

Stocks in Play: WELL Health Technologies Corp.

ABBV

In today's trading, U.S. semiconductor stocks like Nvidia and AMD saw significant declines, while the healthcare sector, led by Eli Lilly and AbbVie, showed gains. The market sentiment is cautious due to concerns over the global chip shortage, but optimism in healthcare suggests a shift in investor interest. Recommendations include increasing healthcare allocations and considering semiconductor stocks for risk-tolerant investors, emphasizing the importance of diversification.

- The U.S. stock market showed mixed results, with technology stocks, notably semiconductors like Nvidia and AMD, experiencing declines amid pressures in the industry.  
- In contrast, the healthcare sector thrived with gains from Eli Lilly and AbbVie due to strong earnings and positive clinical news, attracting investor interest.  
- Strategic recommendations suggest investors increase healthcare sector allocations while considering the semiconductor weaknesses as potential buying opportunities for those willing to endure short-term fluctuations.

Investinglive

Abbvie

Eli Lilly

T-Rex 2X Inverse NVIDIA Daily Target ETF

Direxion Daily NVDA Bear 1X ETF

Direxion Daily NVDA Bull 2X Shares

GraniteShares 2x Long NVDA Daily ETF

Direxion Semicon Bear 3X

Direxion Daily AMD Bear 1X Shares

Direxion Daily AMD Bull 2X Shares

Direxion Daily LLY Bull 2X Shares

AXS 1.5X NVDA Bear Daily ETF

GraniteShares 2x Long AMD Daily ETF

GraniteShares 2x Short NVDA Daily ETF

NVIDIA

Intel

NVIDIA Corporation

Tech turmoil: Semiconductor stocks slide, healthcare finds footing

LLYX

President Trump purchased $680,000 in Eli Lilly (LLY) stock around the FDA's approval of a new weight-loss pill. The timing of these trades coincides with favorable government decisions benefiting Lilly, including a Medicare reimbursement pilot program for GLP-1 drugs. Trump's stock trades, disclosed in ethics forms, include various investments across sectors, but Lilly's trades stand out due to their potential impact on the company's revenue growth, projected to exceed $80 billion in 2026.

Tip Ranks

Defiance Daily Target 2X Long LLY ETF

Microsoft

Boeing

Target

Chipotle Mexican Grill

West Pharmaceutical

Citigroup

Toronto Dominion Bank

Boeing Company

CITIGROUP INC 6.250 NON CUM SER II PFD WI

President Trump Bought Eli Lilly Stock (LLY) as Government Approved Weight-Loss Pill

INCY

LABD

Incyte Stock: Analyst Estimates & Ratings

Barchart Option

Incyte

Direxion S&P Biotech Bear 3X

Incyte Stock: Analyst Estimates & Ratings

Daiwa Securities Group has lowered its target price for Gilead Sciences (NASDAQ:GILD) from $161.00 to $150.00 while maintaining an 'outperform' rating. This new target suggests a potential upside of 14.66%. Other analysts have varied opinions, with Barclays setting a $155.00 target and Wells Fargo raising theirs to $165.00. Gilead's stock is currently trading at $130.82, with a market cap of $162.42 billion and a P/E ratio of 17.85.

Daiwa Securities Group Inc.

Barclays

Wells Fargo

Mizuho Financial

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Mizuho Financial Group, Inc.

Daiwa Securities Group Issues Pessimistic Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price

JPMorgan Chase & Co. has lowered its price target for HCA Healthcare from $535.00 to $490.00, maintaining a 'neutral' rating. The stock currently has a consensus rating of 'Moderate Buy' with an average target price of $515.77. HCA's stock traded down to $405.77, with a market cap of $90.02 billion. Analysts forecast an EPS of 30.07 for the current fiscal year.

HCA Healthcare

JPMorgan Chase

Goldman Sachs

KeyCorp

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

GS Hldg R

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

HCA Healthcare (NYSE:HCA) Price Target Cut to $490.00 by Analysts at JPMorgan Chase & Co.

AbbVie and CVS Health appear expensive with trailing P/E multiples over 40, but non-recurring expenses inflate these figures. AbbVie’s forward P/E is 15, while CVS Health’s is 13, indicating they may be undervalued. AbbVie faced a significant drop in net income due to a $2.7 billion charge, while CVS reported a $4 billion loss from goodwill impairment. Both companies show potential for better performance, making them attractive investment options despite their current valuations.

nasdaq

CVS Health

S&P 500

2 Stocks That Are Much Cheaper Than They Look

iShares Global Healthcare(IXJ.US)

ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD

Here's How Much $100 Invested In BeOne Medicines 10 Years Ago Would Be Worth Today

Sanofi reports 1.21 billion issued shares, 1.33 billion real voting rights as of April 30

Sanofi: Information concerning the total number of voting rights and shares - April 2026

Stocks in Play: WELL Health Technologies Corp.

Tech turmoil: Semiconductor stocks slide, healthcare finds footing

President Trump Bought Eli Lilly Stock (LLY) as Government Approved Weight-Loss Pill

Incyte Stock: Analyst Estimates & Ratings

Daiwa Securities Group Issues Pessimistic Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price

HCA Healthcare (NYSE:HCA) Price Target Cut to $490.00 by Analysts at JPMorgan Chase & Co.

2 Stocks That Are Much Cheaper Than They Look